Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence
- 23 May 2020
- journal article
- review article
- Published by Elsevier BV in Therapies
- Vol. 75 (4), 363-370
- https://doi.org/10.1016/j.therap.2020.05.010
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Effects of Hydroxychloroquine on Immune Activation and Disease Progression Among HIV-Infected Patients Not Receiving Antiretroviral TherapyJAMA, 2012
- In Vitro Cardiovascular Effects of Dihydroartemisin-Piperaquine Combination Compared with Other AntimalarialsAntimicrobial Agents and Chemotherapy, 2012
- A Randomized Controlled Trial of Chloroquine for the Treatment of Dengue in Vietnamese AdultsPLoS Neglected Tropical Diseases, 2010
- Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagyThe Esophagus, 2009
- On Chikungunya Acute Infection and Chloroquine TreatmentVector-Borne and Zoonotic Diseases, 2008
- In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquineBiochemical and Biophysical Research Communications, 2004
- Is Gender a Risk Factor for Adverse Drug Reactions?Drug Safety, 2001
- Randomization Designs in Comparative Clinical TrialsThe New England Journal of Medicine, 1984
- Antihistaminics, local anesthetics, and other amines as antiviral agents.Proceedings of the National Academy of Sciences of the United States of America, 1981
- A New Design for Randomized Clinical TrialsThe New England Journal of Medicine, 1979